1. Home
  2. PPC vs BLTE Comparison

PPC vs BLTE Comparison

Compare PPC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pilgrim's Pride Corporation

PPC

Pilgrim's Pride Corporation

SELL

Current Price

$28.75

Market Cap

6.5B

ML Signal

SELL

Logo Belite Bio Inc

BLTE

Belite Bio Inc

SELL

Current Price

$158.63

Market Cap

6.0B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PPC
BLTE
Founded
1946
2018
Country
United States
United States
Employees
52100
N/A
Industry
Meat/Poultry/Fish
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
6.0B
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
PPC
BLTE
Price
$28.75
$158.63
Analyst Decision
Hold
Strong Buy
Analyst Count
8
9
Target Price
$33.29
★ $228.89
AVG Volume (30 Days)
★ 1.4M
117.1K
Earning Date
10-28-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.48
N/A
Revenue
★ $18,497,553,000.00
N/A
Revenue This Year
$0.27
N/A
Revenue Next Year
$2.28
N/A
P/E Ratio
$59.48
★ N/A
Revenue Growth
★ 3.46
N/A
52 Week Low
$25.13
$78.71
52 Week High
$44.84
$200.00

Technical Indicators

Market Signals
Indicator
PPC
BLTE
Relative Strength Index (RSI) 51.55 44.29
Support Level $27.28 $158.32
Resistance Level $29.90 $161.10
Average True Range (ATR) 0.99 5.48
MACD 0.16 -1.50
Stochastic Oscillator 90.07 33.91

Price Performance

Historical Comparison
PPC
BLTE

About PPC Pilgrim's Pride Corporation

Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed JBS's offer undervalued Pilgrim's Pride.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: